Risankizumab Efficacy and Safety
Approved Indications and Efficacy
- The European Crohn's and Colitis Organisation (ECCO) guidelines provide strong recommendations for risankizumab in Crohn's disease based on high-quality evidence, recommending it for induction and maintenance therapy in moderate-to-severe Crohn's disease 1
- The 2023 EULAR guidelines recognize risankizumab as one of the novel biological DMARDs targeting IL-23-p19 that has shown efficacy for the treatment of psoriatic arthritis 2
Positioning in Treatment Algorithms
- For patients with both psoriatic arthritis and significant skin involvement, IL-23 inhibitors or IL-17 inhibitors are recommended over TNF inhibitors, according to the European League Against Rheumatism (EULAR) recommendations 3
- The EULAR recommendations note that biologicals targeting IL-23-p19 (including risankizumab) appear encouraging, particularly for skin manifestations 3, 4
Safety Profile
- Mild localized infections are a common adverse event associated with risankizumab treatment, as reported in the Annals of the Rheumatic Diseases 3